Journal of Gynecologic Oncology最新文献_第5页

Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study. 微创手术对边缘性卵巢肿瘤和卵巢癌的肿瘤安全性：一项回顾性比较研究。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-15 DOI: 10.3802/jgo.2025.36.e46

Natsuki Osawa, Kenro Chikazawa, Ken Imai, Hiroyoshi Ko, Tomoyuki Kuwata, Ryo Konno

{"title":"Oncological safety of minimally invasive surgery in borderline ovarian tumor and ovarian cancer: a retrospective comparative study.","authors":"Natsuki Osawa, Kenro Chikazawa, Ken Imai, Hiroyoshi Ko, Tomoyuki Kuwata, Ryo Konno","doi":"10.3802/jgo.2025.36.e46","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e46","url":null,"abstract":"Objective: This study aimed to evaluate the oncological safety of laparoscopic surgery for patients with benign tumors who underwent laparoscopic surgery at our facility and were subsequently diagnosed with borderline ovarian tumors or ovarian cancer.Methods: We conducted a retrospective review of 45 patients initially diagnosed with benign ovarian tumors who underwent laparoscopic surgery at our institution from January 2009 to April 2024.Results: Postoperative pathological examination identified 32 cases of borderline ovarian tumors and 13 cases of ovarian cancer. Laparoscopic cystectomy was performed in 14 (43.8%) borderline cases and 4 (30.8%) ovarian cancer cases. Out of 14 patients with borderline ovarian tumors who underwent cystectomy, 8 subsequently underwent staging laparotomy, whereas 6 underwent only ovarian tumor cystectomy. In contrast, none of the patients with ovarian cancer completed treatment with only ovarian tumor cystectomy. Recurrent disease was observed in 9.4% of borderline tumor cases, all of which were successfully managed with further surgery. In the ovarian cancer group, recurrence occurred in 31% of patients, with 3 resulting in tumor-related mortality.Conclusion: Laparoscopic surgery for borderline ovarian tumors is suggested to be oncologically safe, with low recurrence rate and no adverse impact on survival. However, for ovarian cancer, particularly in cases with peritoneal dissemination, rapid disease progression remains a concern. While this study suggests that laparoscopic surgery may be a viable option for borderline ovarian tumors, further research is needed to validate these findings, particularly for ovarian cancer.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetics, toxicities, and tissue concentrations of belotecan sprayed by rotational intraperitoneal pressurized aerosol chemotherapy in a pig model. 在猪模型中通过旋转腹腔加压气雾化疗喷洒贝洛替康的药代动力学、毒性和组织浓度。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-12 DOI: 10.3802/jgo.2025.36.e37

Seungmee Lee, Seoyoon Lee, Yoo-Kyung Song, Se-Mi Kim, Yoon Jeong Choi, Seung Jun Lee, San-Hui Lee, Hee Seung Kim

{"title":"Pharmacokinetics, toxicities, and tissue concentrations of belotecan sprayed by rotational intraperitoneal pressurized aerosol chemotherapy in a pig model.","authors":"Seungmee Lee, Seoyoon Lee, Yoo-Kyung Song, Se-Mi Kim, Yoon Jeong Choi, Seung Jun Lee, San-Hui Lee, Hee Seung Kim","doi":"10.3802/jgo.2025.36.e37","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e37","url":null,"abstract":"Objective: We evaluated the pharmacokinetics, tissue concentrations, and toxicities of belotecan during rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) in pigs.Methods: We sprayed belotecan in 10% and 30% of doses for intravenous chemotherapy in six pigs (cohort 1, n=3, 0.50 mg/m²; cohort 2, n=3, 1.5 mg/m²). We evaluated the time-dependent plasma concentrations of belotecan before RIPAC to 120 hours for the pharmacokinetics, tissue concentrations in twelve peritoneal regions, and hepatic and renal functions before RIPAC to 120 hours in the 2 cohorts.Results: Mean values of the peak plasma concentration (Cmax), the time to Cmax, the time taken for Cmax to drop in half, and the area under the curve from time zero to the time of last quantifiable concentration were 905 and 3,700 ng/mL, 1.42 and 1.50 hours, 3.64 and 5.60 hours, and 2,260 and 17,900 pg·hr/mL in cohorts 1 and 2, respectively. Mean values of tissue concentrations were 1.5 to 15.3 times higher in cohort 1 than in cohort 2 despite the similar ratio of tissue to plasma concentration, and tissue concentrations in the two cohorts were higher in the parietal peritoneum than in the visceral peritoneum. However, hepatic and renal functions were not different before RIPAC to 120 hours in the two cohorts.Conclusion: RIPAC using belotecan of 0.5 mg/m² and 1.5 mg/m² may be feasible with fewer hepatic and renal toxicities in pigs. Thus, belotecan of 1.5 mg/m² may be considered as the starting dose for RIPAC in a phase 1 trial.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functions, interactions and prognostic role of POLE: a bioinformatics analysis. POLE的功能、相互作用和预后作用：生物信息学分析。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-05 DOI: 10.3802/jgo.2025.36.e45

Jonathan Carvajal-Veloza, Fredy Galindo-Morales, Luz Dary Gutierrez-Castañeda

{"title":"Functions, interactions and prognostic role of POLE: a bioinformatics analysis.","authors":"Jonathan Carvajal-Veloza, Fredy Galindo-Morales, Luz Dary Gutierrez-Castañeda","doi":"10.3802/jgo.2025.36.e45","DOIUrl":"https://doi.org/10.3802/jgo.2025.36.e45","url":null,"abstract":"Objective: To describe POLE characteristics and reported mutations in endometrial cancer (EC) and analyze the impact of these mutations on the structure and function of the protein, as well as their relationship with the survival and prognosis of the disease.Methods: We retrieved reported mutations for POLE in EC from Catalogue of Somatic Mutations in Cancer database. We analyzed the most frequent mutations possible impact in the protein using HOPE server. We built a protein-protein network using Network Analyst, Cytoscape, and Network Analyzer plugin for topological analysis, enrichment analysis was performed using Gene Ontology: Biological processes. Clinical data was retrieved from cBioPortal database to compare overall survival between mutated POLE (POLEmut) and wild-type POLE. Relation of mutational status of POLE in EC and immune cell infiltration was analyzed using CIBERSORT algorithm in TIMER2.0 server.Results: Thirty mutations in POLE were retrieved, most reported mutations were p.P286R, p.V411L and p.A456P, these mutations were likely to be pathogenic. Network analysis of POLE showed interaction of this protein in biological processes such as DNA repair, the cell proliferation cycle, and mechanisms of resistance to platinum. Immune infiltration analysis showed that T cell CD8+, T cell memory activated CD4+, T cell follicular helper, T cell gamma delta and macrophage M1 were more infiltrated in EC POLEmut tumors.Conclusion: Mutations in POLE might affect DNA polymerase epsilon function. These mutations also affect interactions with other proteins like proteins involved in different DNA repairing mechanisms. POLE mutations may lead to platinum resistance, but they can also trigger an immune response that improves prognosis.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of cancer in pregnancy on obstetric and neonatal outcomes: an observational retrospective cohort study. 妊娠期癌症对产科和新生儿预后的影响：一项观察性回顾队列研究。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-03-11 DOI: 10.3802/jgo.2024.35.e74

Xuan Huang, Chen Zhang, Jialei Zhu, Yueyan Li, Jing Tang

{"title":"Influence of cancer in pregnancy on obstetric and neonatal outcomes: an observational retrospective cohort study.","authors":"Xuan Huang, Chen Zhang, Jialei Zhu, Yueyan Li, Jing Tang","doi":"10.3802/jgo.2024.35.e74","DOIUrl":"10.3802/jgo.2024.35.e74","url":null,"abstract":"Objective: The study aimed to review the oncological characteristics and treatment of pregnancy-associated cancers and analyze the obstetric and neonatal outcomes to provide evidence-based recommendations for reproductive function preservation, oncological treatment, and obstetric management.Methods: We conducted an observational retrospective cohort study among pregnant patients with cancer in 7 Chinese tertiary A hospitals from 2003 to 2021. We conducted multiple logistic regression to determine the influence of various factors on preterm birth and small-for-gestational-age infants, log-binomial regression to analyze temporal changes, and χ² tests to explore the effects of cancer type/treatment.Results: Of 204 women, 17% terminated their pregnancies; 59% received pre-delivery treatment. Every 6 years, the rates of pregnancy termination (relative risk [RR]=0.48; 95% confidence interval [CI]=0.35-0.67) and iatrogenic preterm births (RR=0.73; 95% CI=0.54-0.98) reduced, and that of pre-delivery treatment increased, mainly due to increased rates of surgery (RR=1.87; 95% CI=1.31-2.67). Maternal systemic diseases were related to small-for-gestational-age infants (odds ratio [OR]=12.02; 95% CI=1.82-79.43). Chemotherapy with taxanes plus platinum-based agents was related to adverse obstetric outcomes (OR=1.87; 95% CI=1.42-2.46; p<0.05). Thyroid (OR=0.36; 95% CI=0.22-0.57) and ovarian cancer (OR=0.70; 95% CI=0.50-0.98) were associated with fewer cesarean sections. Thyroid cancer was associated with fetal growth restriction (OR=5.21; 95% CI=1.21-22.55).Conclusion: Rates of pregnancy termination in cancer declined. Taxane plus platinum-based chemotherapy was associated with adverse obstetric outcomes. Cancer type influenced outcomes.Trial registration: Chinese Clinical Trial Register Identifier: ChiCTR2100044292.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e74"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salvage hysterectomy for persistent residual cervical cancer: assessment of prognostic factors. 针对持续残留宫颈癌的挽救性子宫切除术：预后因素评估。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-30 DOI: 10.3802/jgo.2024.35.e113

Munetaka Takekuma, Koji Matsuo, Shinya Matsuzaki, Mitsuya Ishikawa, Toyomi Satoh

{"title":"Salvage hysterectomy for persistent residual cervical cancer: assessment of prognostic factors.","authors":"Munetaka Takekuma, Koji Matsuo, Shinya Matsuzaki, Mitsuya Ishikawa, Toyomi Satoh","doi":"10.3802/jgo.2024.35.e113","DOIUrl":"10.3802/jgo.2024.35.e113","url":null,"abstract":"In this multicenter retrospective cohort study of 99 patients who underwent salvage hysterectomy for residual disease in the uterine cervix following the completion of definitive radiotherapy for cervical cancer across 25 Japan Clinical Oncology Group-affiliated centers from 2005-2014, (i) time duration from the completion of definitive radiotherapy to the diagnosis of residual disease in the uterine cervix, (ii) salvage hysterectomy surgical margin status, and (iii) extent of residual disease, were independently associated with progression-free survival (PFS). Specifically, (i) time duration to identify residual disease of >62 days was associated with decreased PFS compared to ≤62 days (4-year rates 21.8% vs. 55.0%, adjusted-hazard ratio [aHR]=2.69, 95% confidence interval [CI]=1.55-4.67); (ii) presence of tumor in the surgical margin of hysterectomy specimen was associated with 4 times increased risk of disease progression compared to tumor-free surgical margin (4-year PFS rates 0% vs. 45.3%, aHR=4.27, 95% CI=2.20-8.29); and (iii) hazards of disease progression was 4.5-fold increased when the residual disease extended beyond the uterine cervix compared to residual disease within the uterine cervix only (4-year PFS rates 11.1% vs. 50.6%, aHR=4.54, 95% CI=2.60-7.95). In the absence of these 3 prognostic factors, 4-year PFS rate reached nearly 80% (78.6%, SAL-HYS criteria). In sum, these data suggested that early detection of persistent, residual disease following definitive radiotherapy for cervical cancer may be the key to improve survival if salvage hysterectomy is considered as a tailored treatment option. Ideal surgical candidate would be uterine cervix-contained disease and assurance of adequate tumor-free surgical margin.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e113"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer. 勘误：治疗局部晚期和复发/转移性宫颈癌的最新突破。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.3802/jgo.2024.35.e118

Eduardo García, Natalie Ayoub, Krishnansu S Tewari

引用次数: 0

Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. 化疗反应评分不再预测BRCA基因突变和/或接受维持治疗的高级别浆液性卵巢癌患者的生存结果。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-03-18 DOI: 10.3802/jgo.2024.35.e73

Young Joo Lee, Yoon Kyung Shin, Nae Ry Kim, Se Ik Kim, Yoo-Young Lee, Jeong-Yeol Park, Jae-Weon Kim, Hyun-Woong Cho, Jung-Yun Lee

{"title":"Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy.","authors":"Young Joo Lee, Yoon Kyung Shin, Nae Ry Kim, Se Ik Kim, Yoo-Young Lee, Jeong-Yeol Park, Jae-Weon Kim, Hyun-Woong Cho, Jung-Yun Lee","doi":"10.3802/jgo.2024.35.e73","DOIUrl":"10.3802/jgo.2024.35.e73","url":null,"abstract":"Objective: We aimed to revalidate the chemotherapy response score (CRS) system as a prognostic factor for ovarian cancer patients with breast cancer gene (BRCA) mutations or those receiving frontline poly-ADP ribose polymerase (PARP) inhibitors or bevacizumab as maintenance therapy.Methods: A retrospective analysis was performed using medical records of patients with high-grade serous carcinoma who received neoadjuvant chemotherapy followed by interval debulking surgery between January 2007 and December 2021 at 5 tertiary medical institutions in South Korea. At each hospital, pathologists independently assessed each slide of omental tissues obtained from surgery using the CRS system. Progression-free survival (PFS) and overall survival (OS) values were obtained using Kaplan-Meier analysis to evaluate the effect of BRCA mutation, maintenance therapy, and CRS on survival time.Results: Of 466 patients, BRCA mutations were detected in 156 (33.5%) and 131 (28.1%) were treated with maintenance therapy; 98 (21.0%) and 42 (9.0%) were treated with PARP inhibitors or bevacizumab, respectively. Patients with CRS3 had significantly longer PFS than those with CRS1 or 2 (24.7 vs. 16.8 months, p<0.001). However, there was no significant difference in PFS improvement between CRS3 patients and those with CRS1 or 2 with BRCA mutation (22.0 vs. 19.3 months, p=0.193). Moreover, no significant PFS prolongation was observed in CRS3 patients compared to CRS1 or 2 patients treated with PARP inhibitors or bevacizumab (24.3 vs. 22.4 months, p=0.851; 27.5 vs. 15.7 months, p=0.347, respectively).Conclusion: CRS may not be a prognostic factor in patients with BRCA mutations and those receiving frontline maintenance therapy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e73"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140318450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. 揭示 pembrolizumab 在 MSI 高的子宫内膜癌不同亚型中的有效性。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-05-01 DOI: 10.3802/jgo.2024.35.e103

Risako Ozawa, Tadaaki Nishikawa, Hiroshi Yoshida, Kouya Shiraishi, Tatsunori Shimoi, Tomoyasu Kato, Kan Yonemori

{"title":"Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers.","authors":"Risako Ozawa, Tadaaki Nishikawa, Hiroshi Yoshida, Kouya Shiraishi, Tatsunori Shimoi, Tomoyasu Kato, Kan Yonemori","doi":"10.3802/jgo.2024.35.e103","DOIUrl":"10.3802/jgo.2024.35.e103","url":null,"abstract":"Objective: The efficacy of pembrolizumab in patients with microsatellite instability (MSI)-high cancers has been reported; however, the differences in efficacy according to the subtypes of MSI-high endometrial cancers (ECs) remain unclear. MSI-high ECs are classified into at least 3 groups based on their molecular characteristics: MLH1 hypermethylated, Lynch-like syndrome (LLS)-associated, and Lynch syndrome (LS)-associated cancers. This study aimed to investigate whether the efficacy of pembrolizumab differs among these 3 groups, and if so, whether EPM2AIP1 immunohistochemistry (IHC), which correlates with MLH1 promoter methylation, can be used to rule out MLH1 methylation cases.Methods: This study included 12 patients with MSI-high EC who received pembrolizumab treatment. Patients were categorized into 3 groups based on MLH1 methylation analysis and the Amsterdam Criteria: MLH1 hypermethylated (sporadic [SP]), LLS-associated, and LS-associated. Patients' medical records were retrospectively reviewed, and the efficacy of treatment was evaluated based on the response rate using the Response Evaluation Criteria in Solid Tumors version 1.1.Results: The overall response rate was 75% (3/4) in the SP group, while it was 100% including one complete response patient in the LLS-associated and the LS-associated group, respectively. The sensitivity and positive predictive value of EPM2AIP1 IHC for MLH1 methylation were 100% and 66.7%, respectively.Conclusion: Pembrolizumab may be more effective in LLS and LS-associated groups. EPM2AIP1 IHC was less predictive than MLH1 methylation analysis; however, it may be useful for ruling out MLH1 methylation cases due to its high sensitivity. Further studies are needed to determine whether EPM2AIP1 IHC can predict pembrolizumab efficacy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e103"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic analysis of cervical cancer with lymph node metastasis. 宫颈癌淋巴结转移的基因分析

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-04-29 DOI: 10.3802/jgo.2024.35.e102

Hao He, Misi He, Qi Zhou, Ying Tang, Jing Wang, Xiuying Li, Dongling Zou

{"title":"Genetic analysis of cervical cancer with lymph node metastasis.","authors":"Hao He, Misi He, Qi Zhou, Ying Tang, Jing Wang, Xiuying Li, Dongling Zou","doi":"10.3802/jgo.2024.35.e102","DOIUrl":"10.3802/jgo.2024.35.e102","url":null,"abstract":"Objective: To find out the differences in gene characteristics between cervical cancer patients with and without lymph node metastasis, and to provide reference for therapy.Methods: From January 2018 to June 2022, recurrent cervical cancer patients 39 cases with lymph node metastasis and 73 cases without lymph node metastasis underwent testing of 1,021 cancer-related genes by next-generation sequencing. Maftools software was used to analyze somatic single nucleotide/insertion-deletion variation mutation, co-occurring mutation, cosmic mutation characteristics, oncogenic signaling pathways.Results: EP300 and FBXW7 were significantly enriched in lymph node-positive patients. Lymph node-positive patients with EP300 or FBXW7 mutations had lower overall survival (OS) after recurrence. Both lymph node-positive and -negative patients had plenty of co-occurring mutations but few mutually exclusive mutations. Lymph node-positive co-occurring mutation number ≥6 had lower OS, while lymph node-negative co-occurring mutation number ≥3 had lower OS after recurrence. The etiology of SBS3 was defects in DNA double strand break repair by homologous recombination, which exclusively exist in lymph node-positive patients. There was no difference in median tumor mutation burden (TMB) between positive and negative lymph nodes, but TMB was significantly associated with PIK3CA mutation.Conclusion: The somatic SNV/Indels of EP300 and FBXW7, SBS3 homologous recombination-mediated DNA repair defect were enriched in lymph node-positive patients. For lymph node-positive patients, EP300 or FBXW7 mutations predicted poor prognosis. No matter lymph node-positive or negative, more co-occurring mutation number predicted poor prognosis. PIK3CA mutation may account for the higher TMB and help identify patients who benefit from immunotherapy.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e102"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140850054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prognostic significance of primary tumor site in vulvar cancer: a population-based cohort study. 外阴癌原发肿瘤部位的预后意义：一项基于人群的队列研究。

IF 3.4 2区医学

Journal of Gynecologic Oncology Pub Date : 2024-11-01 Epub Date: 2024-04-23 DOI: 10.3802/jgo.2024.35.e101

Penglin Liu, Xuechao Ji, Zhuang Li, Wenzhi Kong, Zangyu Pan, Mengqi Deng, Jinwei Miao

{"title":"The prognostic significance of primary tumor site in vulvar cancer: a population-based cohort study.","authors":"Penglin Liu, Xuechao Ji, Zhuang Li, Wenzhi Kong, Zangyu Pan, Mengqi Deng, Jinwei Miao","doi":"10.3802/jgo.2024.35.e101","DOIUrl":"10.3802/jgo.2024.35.e101","url":null,"abstract":"Objective: To investigate the association of primary tumor site with prognosis in vulvar cancer, stratified by vulvar squamous cell carcinoma (SCC) and non-SCC histological types.Methods: This population-based retrospective study enrolled patients with vulvar cancer from the Surveillance, Epidemiology, and End Results database between January 2000 and December 2018. The primary outcome was cancer-specific survival (CSS). The prognostic difference between labium majus, labium minus and clitoris groups was investigated using Kaplan-Meier analyses and Cox proportional hazards regression analyses.Results: A total of 3,465 eligible patients with vulvar cancer were included with a mean age of 54.5 years. Among the 1,076 (31.1%) patients with non-SCC, the multivariate Cox regression analyses showed that labium minus-sited disease (hazard ratio [HR]=1.85; 95% confidence interval [CI]=1.27-2.71; p=0.001) and clitoris-sited disease (HR=2.37; 95% CI=1.47-3.85; p<0.001) were significantly associated with worse CSS, compared with labium majus-sited disease. However, among the 2,389 (68.9%) patients with SCC, no significant association of primary tumor site with CSS was found (p>0.05). Kaplan-Meier analyses also showed that the primary tumor site had a significant prognostic effect in vulvar non-SCC (p<0.001) but not in vulvar SCC (p=0.330).Conclusion: Among vulvar non-SCC, patients with labium minus-sited disease had a significantly worse prognosis than those with labium majus-sited disease, and a significantly better prognosis than those with clitoris-sited disease. Gynecologic oncologists should consider the prognostic effect of primary tumor site in vulvar non-SCC, and make optimal, personalized treatment and surveillance strategies based on different primary tumor sites.","PeriodicalId":15868,"journal":{"name":"Journal of Gynecologic Oncology","volume":" ","pages":"e101"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140849887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0